BioCentury | Apr 6, 2019
Finance

Room to rally in 2Q

...are really big on the upside.” On March 4, Ascendis Pharma A/S reported that its TransCon Growth Hormone...
BioCentury | Apr 6, 2019
Finance

Everybody up

...A/S, which announced data on March 4 from the Phase III heiGHt trial showing weekly TransCon growth hormone...
BioCentury | Mar 6, 2019
Financial News

Follow-on roundup: Ascendis, Sarepta

...market close. The company lost $10.70 to $114.70 on Wednesday. Ascendis reported Monday that its TransCon Growth Hormone...
BioCentury | Mar 4, 2019
Clinical News

Ascendis jumps on Phase III readout for once-weekly growth hormone

...Ascendis gained $51.29 (74%) to $120.60 on Monday after reporting that its TransCon Growth Hormone met the primary...
...Stanley, Credit Suisse, Evercore, Wells Fargo, Cantor Fitzgerald, Canaccord Genuity and Wedbush. Chris Lieu, Staff Writer TransCon Growth Hormone (ACP-001) Ascendis...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...end-stage renal disease patients on hemodialysis Phase III data 2019 Ascendis Pharma A/S (NASDAQ:ASND) TransCon Growth Hormone (ACP-001...
BioCentury | Feb 23, 2018
Financial News

Ascendis raises $225M in bumped-up follow-on

...hours to raise $150 million. The company is conducting a Phase III trial of TransCon Growth Hormone (ACP-001...
...completed in October (see BioCentury, Sept. 29, 2017 ). Ascendis Pharma A/S (NASDAQ:ASND), Hellerup, Denmark Paul Bonanos TransCon Growth Hormone Ascendis...
BioCentury | Feb 22, 2018
Financial News

Ascendis, Aimmune price upsized follow-ons

...$1.43 to $59.43 on Thursday. The company is conducting a Phase III trial of TransCon Growth Hormone (ACP-001...
...the primary endpoint in the Phase III PALISADE trial (see BioCentury Extra, Feb. 20) . Paul Bonanos AR101 TransCon Growth Hormone Aimmune...
BioCentury | Sep 29, 2017
Financial News

Ascendis and Catalent price follow-ons

...quarter, Ascendis expects to complete enrollment in the Phase III heiGHt trial evaluating its TransCon Growth Hormone (ACP-001...
...manufacturing, and packaging. Ascendis Pharma A/S (NASDAQ:ASND), Hellerup, Denmark Catalent Inc. (NYSE:CTLT), Somerset, N.J. Elizabeth S. Eaton Somavaratan TransCon Growth Hormone Ascendis...
BioCentury | Sep 27, 2017
Financial News

Follow-on roundup: Ascendis, Catalent

...quarter, Ascendis expects to complete enrollment in the Phase III heiGHt trial evaluating its TransCon Growth Hormone (ACP-001...
...Ascendis was down $2.46 to $34.64 on Wednesday, and Catalent gained $1.06 to $40.27. Elizabeth S. Eaton TransCon Growth Hormone Ascendis...
BioCentury | Sep 22, 2017
Clinical News

Versartis falls on Phase III GHD miss

...its TransCon Growth Hormone (ACP-001) to treat pre-pubertal GHD. Ascendis was off $1.55 to $27.74 on Thursday. Brian Moy ACP-001 Somavaratan TransCon Growth Hormone VRS-317 Amunix...
Items per page:
1 - 10 of 29